Compass Therapeutics Inc. stocks have been trading down by -7.61 percent following impactful clinical trial and regulatory update news.
Click Here for a Millionaire's POV on Trading CMPX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Lead drug tovecimig (CTX-009) missed the overall survival secondary endpoint in the COMPANION-002 Phase 3 trial, with median survival slightly worse than the control arm.
- Shares of Compass Therapeutics dropped roughly 24% after the survival miss, as traders rapidly repriced expectations for CMPX.
- Raymond James cut Compass Therapeutics from Outperform to Market Perform, calling the survival outcome a “true bear” scenario for regulatory and commercial hopes.
- Law firm Johnson Fistel opened an investigation into possible securities law violations and shareholder losses tied to the COMPANION-002 result.
Live Update At 14:02:25 EDT: On Wednesday, April 29, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending down by -7.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CMPX has gone from quiet mid-cap biotech story to full-blown downside momentum in a matter of days. The daily chart shows Compass Therapeutics trading near $5.40–$6.60 for most of April 2026, before collapsing from $5.03 on 2026/04/24 to $1.79 on 2026/04/27 and then grinding to $1.69 by 2026/04/29. That is a brutal multi-day reset where CMPX lost roughly two-thirds of its value.
On the intraday tape, CMPX is now stuck in a tight range around $1.65–$1.75, with five‑minute candles showing low volatility and fading volume. For short-term traders, that signals the initial panic is done, but no real bid has stepped in yet.
More Breaking News
- REPL Stock Collapses As FDA Rejection Triggers Downgrades
- SMR Stock Surges As DOE Loan Support Energizes Nuclear Trade
- American Airlines Stock Pressured As Fuel Costs Soar And Merger Buzz Fades
- NEXR Stock Volatile As Traders Target Deep Value Setup
Fundamentally, Compass Therapeutics is still a development-stage biotech. The latest quarterly report shows no meaningful revenue and a net loss of about $15.7M, or roughly $0.08 per share, with operating cash burn around $13.3M. CMPX does have a sizable cash and short‑term investment pile near $208.9M and a strong current ratio of 15, plus minimal debt. That balance sheet buys time, but with negative returns on equity and assets, the entire equity story for CMPX now leans even harder on what is left in the pipeline after the tovecimig setback.
Why Traders Are Watching CMPX After The “True Bear” Readout
CMPX is on every biotech day trader’s screen right now because this is exactly the type of high‑volatility story that can create both opportunity and pain. Compass Therapeutics disclosed that COMPANION-002, the key Phase 3 study for tovecimig (CTX‑009) in second‑line biliary tract cancer, failed to meet its overall survival secondary endpoint. Median overall survival was actually a bit worse than control, and the statistical adjustment (RPSFT) was described as largely uninterpretable.
For a lead asset, that is a body blow. Traders had been assigning real value to CMPX based on the idea that tovecimig could deliver a credible survival benefit and justify regulatory approval. When that survival signal vanished, the market had to yank a big chunk of implied future cash flows out of the CMPX share price.
The tape showed that repricing in real time. Compass Therapeutics crashed about 24% on the news day, and then kept sliding as more detail around the survival data came out. CMPX is now trading closer to cash and balance‑sheet value than to a rich pipeline premium. Raymond James made that shift explicit, downgrading Compass Therapeutics from Outperform to Market Perform and calling the result a “true bear” scenario. That kind of language from a major firm tells traders that the Street is no longer willing to pay up for CMPX’s tovecimig story.
At the same time, CMPX still has cash, minimal leverage, and other programs. That mix — broken thesis on the lead drug, but not a broken company — often creates sharp dead‑cat bounces, squeeze moves, and choppy consolidation that active traders love to stalk.
Conclusion
For active traders, CMPX is now a classic “hot stove” ticker. Compass Therapeutics just watched its lead program, tovecimig, lose the overall survival narrative in COMPANION-002, with the stock punished accordingly. The downgrade from Raymond James and the “true bear” label crystallized what the chart already showed — confidence in a clean regulatory and commercial path for CTX‑009 has been gutted.
Adding to the overhang, Johnson Fistel’s investigation into potential securities law violations around Compass Therapeutics brings legal and headline risk into the mix. Even if nothing ultimately comes from that probe, it can keep CMPX under pressure and add surprise gap‑down risk around new filings or updates.
At the same time, the strong current ratio, low debt load, and sizable cash position mean Compass Therapeutics is not a textbook bankruptcy story. CMPX now trades near levels where the balance sheet starts to matter more than blue‑sky pipeline hopes, which is exactly when emotion tends to drive intraday swings. For short‑biased traders, failed biotech stories like CMPX can offer clean, technical fades on spikes. For longs, this becomes a pure trading play, not a belief system. This is exactly the kind of setup where discipline around entries and exits matters most. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” That mindset aligns well with the way CMPX now trades — you wait for your levels, respect the risk, and avoid emotional entries into a crowded, volatile biotech ticker.
Tim Sykes likes to remind traders, “Cut losses quickly and don’t fall in love with a stock — especially in biotech where one headline can change everything.” CMPX is living proof of that rule. Use Compass Therapeutics as a real‑time case study: trade the volatility, respect the risk, and always let the chart and the news flow guide your plan.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.